Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. files for Japanese approval of omarigliptin for type 2 diabetes

Nov. 25, 2014

CHMP recommends granting marketing authorization for Shionogi's Senshio

Nov. 25, 2014

Signifor approved in E.U. to treat acromegaly

Nov. 24, 2014

CHMP adopts positive opinion for Genzyme's Cerdelga

Nov. 24, 2014

Palovarotene receives EMA orphan medicinal product designation

Nov. 24, 2014

Nimbus Apollo reports new ACC2 inhibitors

Nov. 24, 2014

Evacetrapib improves cholesterol efflux in patients with dyslipidemia

Nov. 21, 2014

Ajinomoto discloses new GS activators for diabetes

Nov. 20, 2014

Arrowhead Research seeks clearance for phase I trial of ARC-AAT for AAT deficiency

Nov. 19, 2014

Ajinomoto patents glycogen synthase activators

Nov. 19, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...